Monoallelic pathogenic variants in LEPR do not cause obesity

Jérôme Delplanque,Lauriane Le Collen,Hélène Loiselle,Audrey Leloire,Bénédicte Toussaint,Emmanuel Vaillant,Guillaume Charpentier,Sylvia Franc,Beverley Balkau,Michel Marre,Emma Henriques,Emmanuel Buse Falay,Mehdi Derhourhi,Philippe Froguel,Amélie Bonnefond
DOI: https://doi.org/10.1016/j.ajhg.2024.10.014
2024-12-07
The American Journal of Human Genetics
Abstract:This study assessed the impact of heterozygous LEPR variants on monogenic obesity using functional assays. Despite identifying 12 pathogenic variants, no association with obesity or BMI was found, raising concerns about the efficacy of MC4R agonist setmelanotide for individuals with heterozygous LEPR variants in a current clinical trial.
genetics & heredity
What problem does this paper attempt to address?